Compare Abeona Therapeutics Inc (ABEO) vs TotalEnergies SE (TTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs TotalEnergies SE — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while TotalEnergies SE trades at $78.82 (market cap $171.68B). The key difference: TotalEnergies SE is far larger — about 459.9× Abeona Therapeutics Inc's market cap, and TotalEnergies SE pays a 5.41% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TTE | |
|---|---|---|
Market Cap | $373.32M | $171.68B |
Sector | Health | Energy |
52-Week High | $7.23 | $93.60 |
52-Week Low | $4.17 | $57.39 |
Enterprise Value | $228.22M | $205.82B |
Dividend Yield | — | 5.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TotalEnergies (TTE) trades at $77.96, up 1.66% with a bearish technical signal despite recent earnings beat. The stock shows attractive valuation with P/E of 11.32 and P/S of 0.91, supported by stable dividends. Revenue declined to $182.34B in 2025 but net margins improved to 8.2%. Recent developments include new exploration contracts and strategic divestments, while cash flow trends show recovery with 2026 projection of $2.9B net cash flow.
Outlook remains cautiously optimistic given strong analyst buy ratings (57.58%) and value metrics, though bearish technicals and revenue declines pose near-term risks. The company's strategic moves in gas fields and emissions technology provide growth avenues, but regulatory pressures and oil price volatility require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
